Journal: British Journal of Cancer

Article Title: Inhibition of IL-6+IL-6 soluble receptor-stimulated aromatase activity by the IL-6 antagonist, Sant 7, in breast tissue-derived fibroblasts

doi: 10.1038/sj.bjc.6600785

Figure Lengend Snippet: Effect of the IL-6 receptor superantagonist, Sant 7, on IL-6, IL-6sR or IL-6+IL-6sR-stimulated aromatase activity in fibroblasts derived from reduction mammoplasty breast adipose tissue. Fibroblasts were cultured in 2% stripped FCS, phenol red-free EMEM and treatments were added in this medium for 48 h in the presence of dexamethasone (100 n M ). Aromatase activity was measured in intact fibroblast monolayers using [ 3 H-1 β ]androstenedione as the substrate. The significance of differences in treated and control cells was assessed using Student's t -test (a, P <0.001 vs controls; b, P <0.05 vs controls; c, P <0.001 vs IL-6; d, P <0.001 vs IL-6+IL-6sR, means±s.d., n =3).

Article Snippet: The medium was replaced with 2%c. charcoal-stripped FCS, phenol red-free EMEM and treatments were added in this medium for 48 h in the presence of dexamethasone (100 n M ) and included: IL-6+IL-6sR (50 and 100 ng ml −1 , R&D Systems Ltd, Abingdon, Oxon, UK) and PGE 2 (10 μ M , Sigma, Poole, Dorset, UK).

Techniques: Activity Assay, Derivative Assay, Cell Culture, Control

Journal: British Journal of Cancer

Article Title: Inhibition of IL-6+IL-6 soluble receptor-stimulated aromatase activity by the IL-6 antagonist, Sant 7, in breast tissue-derived fibroblasts

doi: 10.1038/sj.bjc.6600785

Figure Lengend Snippet: ( A ) Effect of Sant 7 on IL-6, IL-6sR or IL-6+IL-6sR-stimulated aromatase activity in fibroblasts derived from tissue proximal to a breast tumour. Fibroblasts were cultured in 2% stripped FCS, phenol red-free EMEM and treatments were added in this medium for 48 h in the presence of dexamethasone (100 n M ). Aromatase activity was measured in intact monolayers using [ 3 H-1 β ]androstenedione as the substrate. One set of cells (pretreatment) was preincubated with Sant 7 for 3 h before the addition of IL-6+IL-6sR, while for another set (no pretreatment) Sant 7 was added at the same time as IL-6+IL-6sR (a, P <0.001 vs controls; b, P <0.001 vs IL-6+IL-6sR, means±s.d., n =3). ( B ) Effect of Sant 7 on IL-6 or IL-6+IL-6sR-stimulated aromatase activity in fibroblasts derived from a breast tumour. Culture conditions were as described above (a, P <0.001 vs controls; b, P <0.001 vs IL-6+IL-6sR, means±s.d., n =3).

Article Snippet: The medium was replaced with 2%c. charcoal-stripped FCS, phenol red-free EMEM and treatments were added in this medium for 48 h in the presence of dexamethasone (100 n M ) and included: IL-6+IL-6sR (50 and 100 ng ml −1 , R&D Systems Ltd, Abingdon, Oxon, UK) and PGE 2 (10 μ M , Sigma, Poole, Dorset, UK).

Techniques: Activity Assay, Derivative Assay, Cell Culture

Journal: British Journal of Cancer

Article Title: Inhibition of IL-6+IL-6 soluble receptor-stimulated aromatase activity by the IL-6 antagonist, Sant 7, in breast tissue-derived fibroblasts

doi: 10.1038/sj.bjc.6600785

Figure Lengend Snippet: Ability of Sant 7 to inhibit IL-6+IL-6 sR stimulation of aromatase activity in fibroblasts derived from reduction mammoplasty tissue. Cells were treated for 48 h with IL-6 (50 ng ml −1 ), IL-6sR (100 ng ml −1 ) or Sant 7 (10 μ g ml −1 ), or in combinations as shown, in the absence or presence of dexamethasone (Dex, 100 n M ). Aromatase activity in control cells was 1370±15 fmol 20 h −1 10 6 cells −1 and 639±35 fmol 20h −1 10 6 cells −1 for fibroblasts cultured in the absence or presence of dexamethasone (means±s.d., n =3; a, P <0.05 vs controls; b, P <0.001 vs controls; NS, not significant).

Article Snippet: The medium was replaced with 2%c. charcoal-stripped FCS, phenol red-free EMEM and treatments were added in this medium for 48 h in the presence of dexamethasone (100 n M ) and included: IL-6+IL-6sR (50 and 100 ng ml −1 , R&D Systems Ltd, Abingdon, Oxon, UK) and PGE 2 (10 μ M , Sigma, Poole, Dorset, UK).

Techniques: Activity Assay, Derivative Assay, Control, Cell Culture

Journal: Methods in molecular biology (Clifton, N.J.)

Article Title: Analysis of the Sphingolipidome in NAFLD

doi: 10.1007/978-1-0716-2128-8_22

Figure Lengend Snippet: Supplemented William’s E.

Article Snippet: Supplemented William’s E Media, prepare according to , pre-warmed to 37 °C. table ft1 table-wrap mode="anchored" t5 Table 5: caption a7 William’s E Media 437.5 ml Pen/Strep (10k U/ml) 5 ml L-Glutamine (200 μM) 5 mL Hepes (1M, pH 7.4) 7.5 mL Insulin (Santa Cruz sc-360248) 58 μL Dexamethasone 25 μl FBS 50 mL Open in a separate window Supplemented William’s E. 10x Balanced Salt Solution, prepare according to . table ft1 table-wrap mode="anchored" t5 Table 6: caption a7 NaCl 80 g KCl 4 g MgSO 4 2 g ddH 2 O 1 L Open in a separate window 10x Balanced Salt Solution.

Techniques:

Journal: Molecular metabolism

Article Title: Adipocyte glucocorticoid receptor is important in lipolysis and insulin resistance due to exogenous steroids, but not insulin resistance caused by high fat feeding.

doi: 10.1016/j.molmet.2017.06.013

Figure Lengend Snippet: Figure 2: Dexamethasone administration increases adiposity independently of GR in adipocytes. Flox and AGRKO mice were injected with saline or dexamethasone (Dex, 3 mg/kg body weight) every other day for two months (n ¼ 8e9 per group). (A) Body weight, (B) adipose tissue weights, and (C) histology (H&E staining) of eWAT and iWAT of Flox and AGRKO mice injected with saline or Dex. (D) The distribution of adipocyte size calculated using ImageJ software. Data are shown as mean SEM. Scale bars indicate 100 mm.

Article Snippet: For studies using dexamethasone (Dex), 16-week old littermate Flox and AGRKO mice were administered saline or dexamethasone sodium phosphate (3 mg/kg body weight; Santa Cruz Biotechnology) intraperitoneally every other day for 2 months.

Techniques: Injection, Saline, Staining, Software